View Older Stories View More Recent Stories

May 13, 2016 01:30AM ThromboGenics Business Update - Q1 2016
May 12, 2016 12:00PM EndoStim Secures $25 Million in Funding to Expand Commercialization Efforts and Conduct a Pivotal U.S. Clinical Trial
Apr 27, 2016 02:00AM New Ocriplasmin Research Findings Presented
Apr 21, 2016 06:53AM Novartis (NVS) Misses Q1 EPS by 2c
Apr 21, 2016 01:01AM Novartis delivered solid Q1 despite Gleevec loss of exclusivity; investing behind new launches for long-term growth
Apr 19, 2016 07:00PM Allergies and your eyes: What you need to know this spring by Brandpoint
Apr 12, 2016 11:00AM uStudio Founder Joins CTA Internet Video Initiative
Mar 31, 2016 01:00AM Novartis publishes updated 2015 segment financials reflecting new division structure
Mar 22, 2016 02:22PM Fitch Affirms Ratings of Novartis (NVS) Following Recent Review; Outlook Stable
Mar 10, 2016 09:00AM VisionCare Ophthalmic Technologies Announces Appointment of Industry Veteran, Thierry Clidiere, to its Board of Directors
Mar 1, 2016 02:23AM ThromboGenics to Host R&D Investor Meeting on Novel Disease-Modifying Approaches for Diabetic Eye Disease 18 March in London
Mar 1, 2016 02:00AM ThromboGenics to Host R&D Investor Meeting on Novel Disease-Modifying Approaches for Diabetic Eye Disease 18 March in London
Mar 1, 2016 02:00AM ThromboGenics to Host R&D Investor Meeting on Novel Disease-Modifying Approaches for Diabetic Eye Disease 18 March in London
Feb 18, 2016 01:00AM Alcon expands leadership position in treating glaucoma through acquisition of Transcend Medical, Inc.
Feb 11, 2016 01:59AM Publicis Groupe: 2015 Annual Results
Feb 1, 2016 10:48AM Leading Corporations Find EXHIBITORLIVE a Strategic Marketing Weapon as Attendance and Exhibition Increases
Jan 27, 2016 08:41AM Novartis (NVS) Misses Q4 EPS by 4c; Announces FY16 Strategy, Management Changes
Jan 27, 2016 01:00AM Novartis delivered strong sales growth and core margin expansion (cc[1]) in 2015; announces plans to accelerate growth at Alcon, streamline Group operations
Jan 22, 2016 10:00AM Georgia Bio Deals of the Year Spotlight Financings, Acquisitions and Collaboration
Jan 14, 2016 08:00AM Novartis (NVS) Named Top Global Pharma Pick at Jefferies
Jan 13, 2016 01:35AM ThromboGenics Enrolls First Patient in Phase II CIRCLE Trial
Jan 13, 2016 01:30AM ThromboGenics Enrolls First Patient in Phase II CIRCLE Trial
Jan 13, 2016 01:30AM ThromboGenics Enrolls First Patient in Phase II CIRCLE Trial Evaluating Multiple Doses of Ocriplasmin to Induce a Total Posterior Vitreous Detachment in Patients With Non-Proliferative Diabetic Retino
Jan 11, 2016 07:00AM Ocular TherapeutixTM Strengthens Executive Management Team with the Appointment of Highly Regarded Ophthalmologist Jonathan H. Talamo, M.D., as Chief Medical Officer
Nov 18, 2015 11:50AM ThromboGenics Reports Positive 2 Year Results from the OASIS Study with JETREA(r) (ocriplasmin) for the treatment of Symptomatic VMA/VMT and Macular Hole
Nov 18, 2015 11:40AM ThromboGenics Reports Positive 2 Year Results from the OASIS Study with JETREA® (ocriplasmin) for the treatment of Symptomatic VMA/VMT and Macular Hole
Nov 15, 2015 12:00PM Alcon introduces Contoura Vision as first personalized LASIK procedure at American Academy of Ophthalmology Annual Meeting
Nov 13, 2015 01:37AM ThromboGenics Presents Full OASIS JETREA Trial Data Analysis (incl ERG) and Further Real World Clinical Data at Upcoming AAO 2015 in Las Vegas
Nov 13, 2015 01:30AM ThromboGenics Presents Full OASIS JETREA Trial Data Analysis (incl ERG) and Further Real World Clinical Data at Upcoming AAO 2015 in Las Vegas
Nov 12, 2015 01:35AM ThromboGenics Announces FDA Acceptance of Investigational New Drug (IND) Application for Phase II Study with JETREA(r) for the Treatment of Non-Proliferative Diabetic Retinopathy (CIRCLE)
Nov 12, 2015 01:30AM ThromboGenics Announces FDA Acceptance of Investigational New Drug (IND) Application for Phase II Study with JETREA® for the Treatment of Non-Proliferative Diabetic Retinopathy (CIRCLE)
Nov 5, 2015 11:50AM ThromboGenics Business Update - Q3 2015
Nov 5, 2015 11:40AM ThromboGenics Business Update - Q3 2015
Oct 27, 2015 06:16AM Novartis (NVS) Misses Q3 EPS by 4c
Oct 27, 2015 02:00AM Novartis delivered strong core margin expansion (cc) and continued to strengthen the pipeline in Q3; on track for full-year guidance
Oct 21, 2015 08:00AM Allegro Ophthalmics Names Scott Cooper as Chief Financial Officer and Vice President of Business Development and Mohamed Genead, MD, as Executive Medical Director
Oct 15, 2015 09:00AM Adare Pharmaceuticals Appoints James Jogerst as Vice President, Corporate Development
Oct 8, 2015 04:00PM Marshall B. Ketchum University Raises Over $200,000 at its Fifth Annual Gala on October 1, 2015
Oct 5, 2015 02:25PM Alcon (NVS) Receives FDA Approval for AcrySof IQ Aspheric IOL for Cataract Surgery Patients
Oct 5, 2015 03:09AM MBKU's Southern California College of Optometry Honors 100 Members of the Class of 2019 at the Traditional White Coat Ceremony
Oct 5, 2015 01:15AM Alcon receives FDA Approval for pre-loaded intraocular lens delivery system to treat patients undergoing cataract surgery
Oct 5, 2015 01:15AM Alcon receives FDA Approval for pre-loaded intraocular lens delivery system to treat patients undergoing cataract surgery
Oct 5, 2015 01:15AM Alcon receives FDA Approval for pre-loaded intraocular lens delivery system to treat patients undergoing cataract surgery
Sep 30, 2015 03:12AM PM360 Magazine Announces Winners of 2015 Trailblazer Awards
Sep 22, 2015 09:33AM The Orbis Flying Eye Hospital Returns to Peru for Intensive Medical Training Program
Sep 15, 2015 09:13AM ACETO Corp (ACET) Unit Completes Acquisition of Three ANDAs from Nexus Pharma
Sep 15, 2015 09:12AM ACETO Subsidiary, Rising Pharmaceuticals, Acquires Three FDA-Approved Ophthalmic ANDAs From Nexus Pharmaceuticals
Sep 15, 2015 09:12AM ACETO Subsidiary, Rising Pharmaceuticals, Acquires Three FDA-Approved Ophthalmic ANDAs From Nexus Pharmaceuticals
Sep 10, 2015 12:03PM Baron Philippe Vlerick increases shareholding in ThromboGenics NV to 6.4%
Sep 10, 2015 11:55AM Baron Philippe Vlerick increases shareholding in ThromboGenics NV to 6.4%
View More Recent Stories View Older Stories